Long-term administration of monoamine oxidase inhibitors alters the firing rate and pattern of dopamine neurons in the ventral tegmental area

International Journal of Neuropsychopharmacology

Volumn 12, Issue 4, 2009, Pages 475-485

  Chenu, Franck ^a   Mansari, Mostafa El ^a   Blier, Pierre ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

5 HT3 receptors; Burst activity; Dopamine; Firing rate; MAO inhibitors

Indexed keywords

6 CHLORO 5 METHYL 1 [[2 [(2 METHYL 3 PYRIDYL)OXY] 5 PYRIDYL]CARBAMOYL]INDOLINE; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; CLORGYLINE; DOPAMINE; FENCLONINE; MONOAMINE OXIDASE INHIBITOR; NORADRENALIN; ONDANSETRON; PHENELZINE; SELEGILINE; SEROTONIN; SEROTONIN 3 RECEPTOR; SEROTONIN 2C RECEPTOR; SEROTONIN ANTAGONIST;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC ACTIVITY; DOPAMINERGIC NERVE CELL; DRUG EFFECT; DRUG RECEPTOR BINDING; ELECTRIC ACTIVITY; ELECTROPHYSIOLOGY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SEROTONIN METABOLISM; TREATMENT DURATION; VENTRAL TEGMENTUM; ANIMAL; CYTOLOGY; EVOKED RESPONSE; METABOLISM; NERVE CELL; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; CLORGYLINE; DOPAMINE; ELECTROPHYSIOLOGY; EVOKED POTENTIALS; MALE; MONOAMINE OXIDASE INHIBITORS; NEURONS; NOREPINEPHRINE; PHENELZINE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT2C; RECEPTORS, SEROTONIN, 5-HT3; SELEGILINE; SEROTONIN; SEROTONIN ANTAGONISTS; VENTRAL TEGMENTAL AREA;

EID: 67649230439     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145708009218     Document Type: Article

References (54)

1. Adell A, Artigas F (2004). The somatodendritic release of dopamine in the ventral tegmental area and its regulation by afferent transmitter systems. Neuroscience & Biobehavioral Reviews 28, 415-431.
2. Aghajanian GK, Bunney BS (1977). Dopamine 'autoreceptors': pharmacological characterization by microiontophoretic single cell recording studies. Naunyn Schmiedeberg's Archives of Pharmacology 297, 1-7.
3. Alex KD, Pehek EA (2007). Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission. Pharmacology & Therapeutics 113, 296-320.
4. Aulakh CS, Cohen RM, Dauphin MM, McLellan CA, Murphy DL (1988). Role of serotonergic input in the down-regulation of beta-adrenoceptors following long-term clorgyline treatment. Euroopean Journal of Pharmacology 156, 63-70.
5. 3H]-(S)-zacopride in the forebrain of the rat. Neuropharmacology 29, 1037-1045.
6. Blier P, Bouchard C (1994). Modulation of 5-HT release in the guinea-pig brain following long-term administration of antidepressant drugs. British Journal of Pharmacology 113, 485-495.
7. Blier P, de Montigny C (1985). Serotoninergic but not noradrenergic neurons in rat central nervous system adapt to long-term treatment with monoamine oxidase inhibitors. Neuroscience 16, 949-955.
8. Blier P, de Montigny C, Azzaro AJ (1986a). Effect of repeated amiflamine administration on serotonergic and noradrenergic neurotransmission: electrophysiological studies in the rat CNS. Naunyn Schmiedeberg's Archives of Pharmacology 334, 253-260.
9. Blier P, de Montigny C, Azzaro AJ (1986b). Modification of serotonergic and noradrenergic neurotransmissions by repeated administration of monoamine oxidase inhibitors: electrophysiological studies in the rat central nervous system. Journal of Pharmacology and Experimental Therapeutics 237, 987-994.
10. Bourin M, Mocaer E, Porsolt R (2004). Antidepressant-like activity of S20098 (agomelatine) in the forced swimming test in rodents: involvement of melatonin and serotonin receptors. Journal of Psychiatry and Neuroscience 29, 126-133.
11. Campbell AD, Kohl RR, McBride WJ (1996). Serotonin-3 receptor and ethanol-stimulated somatodendritic dopamine release. Alcohol 13, 569-574.
12. Celada P, Artigas F (1993). Monoamine oxidase inhibitors increase preferentially extracellular 5-hydroxytryptamine in the midbrain raphe nuclei. A brain microdialysis study in the awake rat. Naunyn Schmiedeberg's Archives of Pharmacology 347, 583-590.
13. Chen J, Paredes W, Van Praag HM, Lowinson JH, Gardner EL (1992). Presynaptic dopamine release is enhanced by 5-HT3 receptor activation in medial prefrontal cortex of freely moving rats. Synapse 10, 264-266.
14. Dailly E, Chenu F, Renard CE, Bourin M (2004). Dopamine, depression and antidepressants. Fundamental Clinical Pharmacology 18, 601-607.
15. Dremencov E, Blier P, El Mansari M (2008). Effects of sustained serotonin reuptake inhibition on the firing activity of catecholamine neurons. Biological Psychiatry 63 (Suppl.), 79S.
16. El Mansari M, Ghanbari R, Janssen S, Blier P (in press). Sustained administration of bupropion alters serotonin and norepinephrine but not dopamine firing activity in the rat brain. Neuropharmacology.
17. Esposito E (2006). Serotonin-dopamine interaction as a focus of novel antidepressant drugs. Current Drug Targets 7, 177-185.
18. Evrard A, Malagie I, Laporte AM, Boni C, Hanoun N, Trillat AC, Seif I, De Maeyer E, Gardier A, Hamon M, Adrien J (2002). Altered regulation of the 5-HT system in the brain of MAO-A knock-out mice. European Journal of Neuroscience 15, 841-851.
19. Ferrer A, Artigas F (1994). Effects of single and chronic treatment with tranylcypromine on extracellular serotonin in rat brain. European Journal of Pharmacology 263, 227-234.
20. Finberg JP, Pacak K, Kopin IJ, Goldstein DS (1993). Chronic inhibition of monoamine oxidase type A increases noradrenaline release in rat frontal cortex. Naunyn Schmiedeberg's Archives of Pharmacology 347, 500-505.
21. Grace AA, Bunney BS (1983). Intracellular and extracellular electrophysiology of nigral dopaminergic neurons - 1. Identification and characterization. Neuroscience 10, 301-315.
22. Grace AA, Bunney BS (1984). The control of firing pattern in nigral dopamine neurons: burst firing. Journal of Neuroscience 4, 2877-2890.
23. Grace AA, Floresco SB, Goto Y, Lodge DJ (2007). Regulation of firing of dopaminergic neurons and control of goal-directed behaviors. Trends in Neuroscience 30, 220-227.
24. Grenhoff J, North RA, Johnson SW (1995). Alpha 1-adrenergic effects on dopamine neurons recorded intracellularly in the rat midbrain slice. European Journal of Neuroscience 7, 1707-1713.
25. Guan XM, McBride WJ (1989). Serotonin microinfusion into the ventral tegmental area increases accumbens dopamine release. Brain Research Bulletin 23, 541-547.
26. Guiard BP, El Mansari M, Merali Z, Blier P (2008). Functional interactions between dopamine, serotonin and norepinephrine neurons: an in-vivo electrophysiological study in rats with monoaminergic lesions. International Journal of Neuropsychopharmacology 11, 625-639.
27. Haddjeri N, De Montigny C, Curet O, Blier P (1998). Effect of the reversible monoamine oxidase-A inhibitor befloxatone on the rat 5-hydroxytryptamine neurotransmission. European Journal of Pharmacology 343, 179-192.
28. Hamon M (1992). Central and Peripheral 5-HT3 Receptors. New York: Academic Press.
29. Invernizzi R, Pozzi L, Samanin R (1995). Selective reduction of extracellular dopamine in the rat nucleus accumbens following chronic treatment with DAU 6215, a 5-HT3 receptor antagonist. Neuropharmacology 34, 211-215.
30. Jiang LH, Ashby Jr. CR, Kasser RJ, Wang RY (1990). The effect of intraventricular administration of the 5-HT3 receptor agonist 2-methylserotonin on the release of dopamine in the nucleus accumbens: an in vivo chronocoulometric study. Brain Research 513, 156-160.
31. Johnston JP (1968). Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochemical Pharmacology 17, 1285-1297.
32. Kalivas PW, Bourdelais A, Abhold R, Abbott L (1989). Somatodendritic release of endogenous dopamine: in vivo dialysis in the A10 dopamine region. Neuroscience Letters 100, 215-220.
33. Knoll J, Magyar K (1972). Some puzzling pharmacological effects of monoamine oxidase inhibitors. Advances in Biochemical Psychopharmacology 5, 393-408.
34. Koyama S, Matsumoto N, Murakami N, Kubo C, Nabekura J, Akaike N (2002). Role of presynaptic 5-HT1A and 5-HT3 receptors in modulation of synaptic GABA transmission in dissociated rat basolateral amygdala neurons. Life Sciences 72, 375-387.
35. Krishnan KR (2007). Revisiting monoamine oxidase inhibitors. Journal of Clinical Psychiatry 68 (Suppl. 8), 35-41.
36. Lamensdorf I, Youdim MB, Finberg JP (1996). Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo. Journal of Neurochemistry 67, 1532-1539.
37. 3H]zacopride as radioligands. Synapse 10, 271-281.
38. Li SX, Perry KW, Wong DT (2002). Influence of fluoxetine on the ability of bupropion to modulate extracellular dopamine and norepinephrine concentrations in three mesocorticolimbic areas of rats. Neuropharmacology 42, 181-190.
39. Lipper S, Murphy DL, Slater S, Buchsbaum MS (1979). Comparative behavioral effects of clorgyline and pargyline in man: a preliminary evaluation. Psychopharmacology (Berlin), 62, 123-128.
40. Liu W, Thielen RJ, Rodd ZA, McBride WJ (2006). Activation of serotonin-3 receptors increases dopamine release within the ventral tegmental area of Wistar and alcohol-preferring (P) rats. Alcohol 40, 167-176.
41. Mann JJ, Aarons SF, Frances AJ, BrownRD (1984). Studies of selective and reversible monoamine oxidase inhibitors. Journal of Clinical Psychiatry 45, 62-66.
42. Marinelli M, Rudick CN, Hu XT, White FJ (2006). Excitability of dopamine neurons: modulation and physiological consequences. CNS & Neurological Disorders - Drug Targets 5, 79-97.
43. Mateo Y, Fernandez-Pastor B, Meana JJ (2001). Acute and chronic effects of desipramine and clorgyline on alpha(2)-adrenoceptors regulating noradrenergic transmission in the rat brain: a dual-probe microdialysis study. British Journal of Pharmacology 133, 1362-1370.
44. 3H]noradrenaline in the rat hippocampus. European Journal of Pharmacology 271, 121-129.
45. Nomikos GG, Damsma G, Wenkstern D, Fibiger HC (1989). Acute effects of bupropion on extracellular dopamine concentrations in rat striatum and nucleus accumbens studied by in vivo microdialysis. Neuropsychopharmacology 2, 273-279.
46. 3H]quipazine in rodent brain. European Journal of Pharmacology 187, 75-85.
47. Pineyro G, Blier P (1999). Autoregulation of serotonin neurons: role in antidepressant drug action. Pharmacological Reviews 51, 533-591.
48. Ramamoorthy R, Radhakrishnan M, Borah M (2008). Antidepressant-like effects of serotonin type-3 antagonist, ondansetron: an investigation in behaviour-based rodent models. Behavioural Pharmacology 19, 29-40.
49. Redrobe JP, Bourin M(1997). Partial role of 5-HT2 and 5-HT3 receptors in the activity of antidepressants in the mouse forced swimming test. European Journal of Pharmacology 325, 129-135.
50. Robinson DS (2002). Monoamine oxidase inhibitors: a new generation. Psychopharmacological Bulletin 36, 124-138.
51. Ropert N, Guy N (1991). Serotonin facilitates GABAergic transmission in the CA1 region of rat hippocampus in vitro. Journal of Physiology 441, 121-136.
52. Ungless MA, Magill PJ, Bolam JP (2004). Uniform inhibition of dopamine neurons in the ventral tegmental area by aversive stimuli. Science 303, 2040-2042.
53. White FJ, Wang RY (1984). Pharmacological characterization of dopamine autoreceptors in the rat ventral tegmental area: microiontophoretic studies. Journal of Pharmacology and Experimental Therapeutics 231, 275-280.
54. Willner P (1997). The mesolimbic dopamine system as a target for rapid antidepressant action. International Clinical Psychopharmacology 12 (Suppl. 3), S7-14.